|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
585,690,000 |
Market
Cap: |
158.12(B) |
Last
Volume: |
2,436,955 |
Avg
Vol: |
2,722,982 |
52
Week Range: |
$214.27 - $324.56 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 499 |
Guru Rank Value : 3 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
12,096 |
21,654 |
43,486 |
Total Sell Value |
$0 |
$3,300,412 |
$5,808,718 |
$11,189,871 |
Total People Sold |
0 |
2 |
3 |
6 |
Total Sell Transactions |
0 |
2 |
3 |
9 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Reese David M |
EVP, Research and Development |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,989 |
52,714 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
34,964 |
630,141 |
|
- |
|
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,992 |
52,487 |
|
- |
|
Gordon Murdo |
EVP Global Commercial Ops |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,989 |
49,682 |
|
- |
|
Khosla Rachna |
SVP, Business Development |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
7,139 |
|
- |
|
Johnston Lori A |
EVP, HR |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,495 |
40,881 |
|
- |
|
Khosla Rachna |
SVP, Business Development |
|
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,104 |
6,185 |
|
- |
|
Grygiel Nancy A. |
SVP & CCO |
|
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
935 |
13,547 |
|
- |
|
Holley Charles M |
Director |
|
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
187 |
5,703 |
|
- |
|
Kullman Ellen Jamison |
Director |
|
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
152 |
8,477 |
|
- |
|
Louie Linda H. |
VP, Finance & CAO |
|
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
350 |
8,647 |
|
- |
|
Gordon Murdo |
EVP Global Commercial Ops |
|
2021-11-02 |
4 |
D |
$209.79 |
$1,171,677 |
D/D |
(5,585) |
39,602 |
|
- |
|
Reese David M |
EVP, Research and Development |
|
2021-11-02 |
4 |
D |
$209.74 |
$459,750 |
D/D |
(2,192) |
42,593 |
|
- |
|
Griffith Peter H. |
EVP & CFO |
|
2021-11-01 |
4 |
D |
$206.97 |
$550,747 |
D/D |
(2,661) |
23,700 |
|
- |
|
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2021-11-01 |
4 |
D |
$206.97 |
$329,289 |
D/D |
(1,591) |
45,353 |
|
- |
|
Johnston Lori A |
EVP, HR |
|
2021-11-01 |
4 |
D |
$206.97 |
$279,823 |
D/D |
(1,352) |
36,269 |
|
- |
|
Khosla Rachna |
SVP, Business DevelopmentOffic |
|
2021-09-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,068 |
|
4% |
|
Kullman Ellen Jamison |
Director |
|
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
282 |
8,263 |
|
- |
|
Ishrak Omar |
Director |
|
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
760 |
935 |
|
- |
|
Holley Charles M |
Director |
|
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
348 |
5,473 |
|
- |
|
Ishrak Omar |
Director |
|
2021-07-29 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
175 |
|
- |
|
Druker Brian |
Director |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
3,634 |
|
- |
|
Eckert Robert |
Director |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
13,199 |
|
- |
|
Sugar Ronald D |
Director |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
16,764 |
|
- |
|
Miles Amy E |
Director |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
1,245 |
|
- |
|
2150 Records found
|
|
Page 9 of 86 |
|
|